Rates of major bleeding with rivaroxaban in real-world studies of nonvalvular atrial fibrillation patients: a meta-analysis

Abstract

Numerous real-world studies estimating major bleeding rates in rivaroxaban patients with nonvalvular atrial fibrillation have been published. We performed a meta-analysis to better quantify the rates of different types of major bleeding seen with rivaroxaban in observational studies. The pooled rates of major bleeding with rivaroxaban were generally low and consistent with those reported in its pivotal randomized controlled trial.

Keywords:

• Major bleeding
• Meta-analysis
• Nonvalvular atrial fibrillation
• Rivaroxaban

Declaration of funding

This study was not funded. Publication support was paid for by the authors.

Declaration of financial/other relationships

C.I.C. has disclosed that he has received grant funding and/or consultancy fees from Janssen Pharmaceuticals, Pfizer and Boehringer Ingelheim Pharmaceuticals. W.F.P. has disclosed that he has obtained research grants from Abbott, Alere, Banyan, Cardiorentis, Portola, Roche, and The Medicines Company; served as a consultant for Alere, BG Medicine, Beckman, Boehringer-Ingelheim, Cardiorentis, Instrument Labs, Janssen, Prevencio, The Medicines Company, and ZS Pharma; and has ownership interests in Comprehensive Research Associates LLC and Emergencies in Medicine LLC. E.R.W. and C.M.W. have disclosed that they have no significant relationships with or financial interests in any commercial companies related to this study or article.

CMRO peer reviewer 1 has disclosed that he has received honoraria for lectures from Bayer and Boehringer Ingleheim. CMRO peer reviewer 2 has no relevant financial or other relationships to disclose.